Management of hepatocellular carcinoma.

@article{Bruix2005ManagementOH,
  title={Management of hepatocellular carcinoma.},
  author={Jordi Bruix and Morris Sherman},
  journal={Hepatology},
  year={2005},
  volume={42 5},
  pages={
          1208-36
        }
}
  • Jordi Bruix, Morris Sherman
  • Published in Hepatology 2005
  • Medicine
  • The incidence of hepatocellular carcinoma (HCC) has increased worldwide and is now the 5th most frequent cancer representing approximately 5% of all cancers worldwide. More than 500,000 new cases are diagnosed per year and it is the third cause of cancer-related death and the first cause of death in patients with cirrhosis [1]. The incidence of HCC has major geographical differences, but most patients diagnosed with HCC have underlying cirrhosis. The highest risk is observed in cirrhosis from… CONTINUE READING

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This study is a phase II, prospective, open-label, single arm, single center study of the efficacy and safety of concurrent conventional transarterial chemoembolization (TACE) and… Expand
    ConditionsHepatocellular Carcinoma, Metastasis
    InterventionDrug, Procedure
    INTERVENTIONAL CLINICAL TRIAL
    Study Phase: multi-institutional Phase II study Primary Objective(s): To determine overall survival for HCC patients treated with CyberKnife SBRT at 2 years. Secondary Objective(s… Expand
    ConditionsLiver Neoplasms
    InterventionRadiation
    INTERVENTIONAL CLINICAL TRIAL
    TACE is considered the standard treatment for unresectable HCC and is widely used as a palliative treatment. However there is no consensus of the protocol of TACE.One of the… Expand
    ConditionsHepatocellular Carcinoma
    InterventionOther
    INTERVENTIONAL CLINICAL TRIAL
    In unresectable hepatocellular carcinoma, TACE using Lipiodol/anti cancer agent emulsion is the standard treatment and reported as a significantly better treatment through randomized… Expand
    ConditionsHepatocellular Carcinoma
    InterventionProcedure

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 2,250 CITATIONS, ESTIMATED 41% COVERAGE

    Hepatocellular carcinoma and other hepatic malignancies: MR imaging.

    VIEW 12 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm.

    VIEW 5 EXCERPTS
    HIGHLY INFLUENCED

    Surgical Management of HCC

    VIEW 11 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    FILTER CITATIONS BY YEAR

    2004
    2020

    CITATION STATISTICS

    • 228 Highly Influenced Citations

    • Averaged 113 Citations per year from 2017 through 2019

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 342 REFERENCES

    Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular carcinoma treated by liver transplantation?

    Percutaneous radiofrequency ablation for hepatocellular carcinoma

    • R Tateishi, S Shiina, +3 authors Y Koike
    • An analysis of 1000 cases. Cancer 2005;103:1201-1209
    • 2005